Results

• All
• Video
• Audio
• Images

• Most recent
• Filter by category

1–3 of 3 results for protocol AC

• 

  Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results

  Dilraj S Grewal, MD, FASRS

  Annual Meeting Talks

  2023

• 

  Cost-Effectiveness of Aflibercept Monotherapy vs Bevacizumab-First Followed by Switching to Aflibercept if Needed for Diabetic Macular Edema

  Mathew W. MacCumber, MD, PhD

  Annual Meeting Talks

  2023

• 

  Expert Panel: Socioeconomics

  Linda A. Lam, MD, MBA, FASRS

  Ella H Leung, MD

  Mohsin H. Ali, MD

  Hasenin Al-khersan, MD

  Miguel A. Busquets, MD, FACS

  Annual Meeting Talks

  2024